Reading time – 6 minutes  


Trilaciclib is one of the most anticipated drugs of 2021. More than 2 million patients around the world need it. Because of these circumstances, the Food and Drug Administration made it a priority to review drug approval. And on Feb. 12, 2021, some 2 million patients got the good news: the FDA approved a new drug to alleviate the effects after treatment of small-cell lung cancer with chemotherapy. Since our December article on promising cancer treatments in 2021, MediGlobus has often been contacted by patients who want to know the availability of this drug. And in this article, we’ll tell our readers how the most anticipated drug of 2021 works, what its effectiveness is, and which clinics can provide treatment with Trilaciclib. Read to the end!

 

 

WHAT IS COSELA (TRILACICLIB)?

 

    Trilaciclib is a substance that is part of the drug Cosela. Cosela is a drug that the FDA has approved to treat the effects of chemotherapy for small-cell lung cancer. Cosela is manufactured by G1 Therapeutics, an American pharmaceutical company. Trilaciclib received breakthrough therapy status from the FDA in 2019.

     

    Записаться на курс лечения Трилациклибом

иконка галочки   SMALL CELL LUNG CANCER


Small cell lung cancer is a rare diagnosis that occurs in 13% of patients with lung cancer. The five-year survival rate is 16-27%. Chemotherapy is the main treatment, but it damages the bone marrow, the organ that provides immunity.

 

    The FDA approved Cosela (Trilaciclib) on February 12, 2021, in a priority review format.

 

Trilaciclib is prescribed to:

 

    иконка галочки reduce the severity of bone marrow damage after chemotherapy;  

    иконка галочки preserve more white and red blood cells and platelets;  

    иконка галочки reduce the risk of infection in patients; 

    иконка галочки reduce the risk of anaemia.  

Trilacyclib (cosela) non-small lung cancer

 

    WHY IS TRILACICLIB APPROVAL SO IMPORTANT?

    Small-cell lung cancer is treated with high-dose chemotherapy. It can prolong life and markedly reduce symptoms. However, intensive chemotherapy leads to myelosuppression – damage to the bone marrow.

     

    Trilaciclib is the first drug that lessens the side effects of chemotherapy and protects the bone marrow. After taking the drug, patients are less likely to get infections and anaemia (lack of blood cells). For this reason, they do not need a bone marrow transplant, an expensive surgery that can restore bone marrow function. This would save $50,000 in treatment for the side effects of chemotherapy.

 

Sign up for treatment with Cosela

EXPERTS’ OPINION ON THE COSELA (TRILACICLIB)

 

FDA HAS APPROVED TRILACICLIB FOR TREATMENT OF NON-SMALL LUNG CANCER

“The approval of Trilaciclib (Cosela) is an important advance in the treatment of patients with advanced small-cell lung cancer receiving chemotherapy,” reports Professor Jeffrey Crawford of Duke Cancer Institute.

 

“Standard chemotherapy regimens damage bone marrow function and can lead to costly hospitalizations and surgeries. Cosela is the first and only therapy that helps protect bone marrow from chemotherapy-induced myelosuppression,” explains Jack Bailey, CEO of pharmaceutical company G1.

 

“For patients with stage 4 small-cell lung cancer, protecting bone marrow function can help make their chemotherapy safer and allow them to complete their treatment on time and as planned,” reports Albert Deisseroth, a doctor at the FDA’s Center for Drug Evaluation and Research.

 

Sign up for treatment with Cosela

INDICATIONS AND CONTRAINDICATIONS FOR TRILACICLIB

 

    Trilaciclib is prescribed for patients with stage 3-4 small-cell lung cancer who have had chemotherapy.

 

The drug is contraindicated in people with pneumonitis and interstitial lung disease. Treatment with Cosela should not be given to patients with hypersensitivity to Trilaciclib. Pregnant women are also contraindicated for this therapy.

 

    Between 2021 and 2022, medical professionals will test the efficacy and safety of Trilaciclib for stage 4 colorectal cancer, triple-negative breast cancer and bladder cancer.

 

HOW TRILACICLIB WORKS FOR LUNG CANCER

 

The main active ingredient in Cosela is Trilaciclib. It inhibits the activity of CDK 4/6. This means that the drug blocks the work of different kinds of cyclin-dependent kinases – enzymes that control cell activity. Suppression of CDK 4/6 activity interrupts the process of cancer cell division. This strategy works effectively to treat metastatic cancer. Additionally, it helps protect cells from the damaging effects of chemotherapeutic agents.

 

    For Cosela to be effective, it has to be administered intravenously as an infusion. One session lasts about 30 minutes. During chemotherapy, the patient should receive at least 1 session.

 

TRILACICLIB EFFICACY IN LUNG CANCER

 

The combination of chemotherapy and Cosela (Trilaciclib) prolongs and improves the lives of patients with small-cell lung cancer. They can receive chemotherapy without lowering the dose or reducing the number of courses while avoiding serious side effects.

 

Trilaciclib reduces the risk of neutropenia and preserves immune function. Patients feel better during therapy due to a reduction side effects of chemotherapy. After a course of Trilaciclib, patients are less prone to infections.

 

Thanks to Cosela (Trilaciclib), patients do not need blood transfusions or bone marrow transplants.

Trilacyclib (cosela) non-small lung cancer

SIDE EFFECTS OF TRILACICLIB

 

About 30% of patients have difficulty breathing, low levels of calcium, potassium, and phosphate in the blood, and an increased risk of blood clots. About 10% of patients report increased fatigue and headache.

 

WHERE TO GET TRILACICLIB TREATMENT

 

Trilaciclib is available at advanced clinics that specialize in oncology. Going to foreign clinics can ensure that you get the original drug. You will be monitored by an experienced team of doctors who will help you if you have any serious side effects. You can get therapy with the Cosela at:

 

 

 

 

    Resume

    иконка галочкиTrilaciclib is the main active ingredient in Cosela. It is prescribed to alleviate the effects of chemotherapy for patients with small-cell lung cancer. 

    иконка галочкиTrilaciclib protects bone marrow cells. After a course of Cosela, patients are less likely to get an infection. They are also less likely to develop anaemia. 

    иконка галочкиA course of Trilaciclib can help a patient avoid costly rehabilitation after chemotherapy. For example, the patient will not need a blood transfusion or bone marrow transplant. After taking the drug, patients sometimes notice difficulty breathing and fatigue.  

    иконка галочки The FDA has declared the drug safe. After taking the drug, patients sometimes notice difficulty breathing and fatigue.  

    иконка галочки Trilaciclib treatment is available at the Liv Hospital in Turkey, Brno University clinic in the Czech Republic, Cologne University Hospital in Germany, and the University hospital of Navarra in Spain.  

Submit a request for Cosela treatment

Our coordinators are ready to advise you and tell about the nuances of the medical trip. Call us or leave your contact details. We will call you back and answer all your questions. Our services are free of charge.

Get a free consultation


Sources:

 

  1. 1. Small cell lung cancer – basic statistics
  2. 2. Official FDA approval of Trilaciclib
  3. 3. Information about Trilaclib on the G1 Therapeutics website
  4. 4. What is Cosela (Trilaciclib)


Related posts

A new proton therapy center in Navarra, Spain

Surgery for lung cancer

Advances in Spanish medicine in cancer treatment